David M. Aboulafia
Experienced in Pure Red Cell Aplasia

Dr. David M. Aboulafia

Hematology Oncology | Hematology | Oncology
Virginia Mason Medical Center
925 Seneca St, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Experienced in Pure Red Cell Aplasia
Virginia Mason Medical Center
925 Seneca St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Aboulafia is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Aboulafia is rated as an Experienced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Non-Hodgkin Lymphoma, Anal Cancer, Kaposi Sarcoma, B-Cell Lymphoma, and Splenectomy. Dr. Aboulafia is currently accepting new patients.

His clinical research consists of co-authoring 73 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Virginia Mason Medical Center
Kadlec Regional Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

VIRGINIA MASON MEDICAL CENTER
925 Seneca St, Seattle, WA 98101
Other Locations
VIRGINIA MASON MEDICAL CENTER
7315 212th St Sw, Suite 101, Edmonds, WA 98026
VIRGINIA MASON MEDICAL CENTER
4575 Sand Point Way Ne, Suite 108, Seattle, WA 98105
VIRGINIA MASON MEDICAL CENTER
11800 Ne 128th St, Suite 300, Kirkland, WA 98034
VIRGINIA MASON MEDICAL CENTER
10601 5th Ave Ne, Suite 201 West, Seattle, WA 98125
VIRGINIA MASON MEDICAL CENTER
33501 1st Way S, Federal Way, WA 98003
VIRGINIA MASON MEDICAL CENTER
2671 Ne 46th St, Seattle, WA 98105
VIRGINIA MASON MEDICAL CENTER
100 Ne Gilman Blvd, Issaquah, WA 98027
VIRGINIA MASON MEDICAL CENTER
380 Winslow Way E, Bainbridge Island, WA 98110
VIRGINIA MASON MEDICAL CENTER
19116 33rd Ave W, Lynnwood, WA 98036

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: September 23, 2025
Intervention Type: Biological, Procedure
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Vinblastine
Study Phase: Phase 1/Phase 2
A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
Enrollment Status: Completed
Publish Date: July 23, 2025
Intervention Type: Drug, Other
Study Drugs: Imiquimod, Fluorouracil
Study Phase: Phase 3
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Enrollment Status: Terminated
Publish Date: May 11, 2025
Intervention Type: Other, Genetic
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: April 18, 2025
Intervention Type: Behavioral, Other, Biological
Study Drug: Recombinant EphB4-HSA Fusion Protein
Study Phase: Phase 2
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Procedure
Study Phase: Phase 2
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Apilimod, Rituximab, Atezolizumab
Study Phase: Phase 1
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Device, Other
Study Drugs: Imiquimod, 5-Fluorouracil
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Other, Drug
Study Drug: Nelfinavir Mesylate
Study Phase: Phase 2
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Enrollment Status: Terminated
Publish Date: March 16, 2023
Intervention Type: Other, Genetic
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug, Other
Study Drug: Cabozantinib S-malate
Study Phase: Phase 1
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

73 Total Publications

Cancer Drugs and United States Tariffs: Attention Must Be Paid.
Cancer Drugs and United States Tariffs: Attention Must Be Paid.
Journal: Cancer journal (Sudbury, Mass.)
Published: May 29, 2025
Similar Doctors
Elite in Pure Red Cell Aplasia
Dr. Janis L. Abkowitz
Hematology Oncology | Hematology | Oncology
Elite in Pure Red Cell Aplasia
Dr. Janis L. Abkowitz
Hematology Oncology | Hematology | Oncology
Seattle Cancer Care Alliance, 825 Eastlake Avenue East, 
Seattle, WA 
 (1.7 miles away)
206-288-1012
Languages Spoken:
English, French, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Janis Abkowitz is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Abkowitz is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Aplastic Anemia, Transient Erythroblastopenia of Childhood, and Bone Marrow Aspiration. Dr. Abkowitz is currently accepting new patients.

Elite in Pure Red Cell Aplasia
Dr. Sioban B. Keel
Hematology
Elite in Pure Red Cell Aplasia
Dr. Sioban B. Keel
Hematology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.1 miles away)
206-288-1000
Languages Spoken:
English, French, German, Hindi, Russian, Spanish, Swedish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sioban Keel is a Hematologist in Seattle, Washington. Dr. Keel is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Porphyria, Acute Hepatic Porphyria (AHP), Pure Red Cell Aplasia, Acute Intermittent Porphyria, and Bone Marrow Aspiration. Dr. Keel is currently accepting new patients.

Advanced in Pure Red Cell Aplasia
Dr. Daniel B. Martin
Hematology Oncology | Hematology | Oncology
Advanced in Pure Red Cell Aplasia
Dr. Daniel B. Martin
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

908 Jefferson St, 
Seattle, WA 
 (0.4 miles away)
206-744-2020
Languages Spoken:
English, Filipino, French, Icelandic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Martin is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Martin is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Sideroblastic Anemia, Polycythemia Vera, and Bone Marrow Aspiration. Dr. Martin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aboulafia's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 33 Advanced Conditions
View All 126 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile